Antibody to hepatitis B core antigen-positive grafts: Not perfect but no longer marginal

Liver Transplantation

Volumn 15, Issue 10, 2009, Pages 1164-1168

  Prieto, Martín ^a,b  

^a HOSPITAL UNIVERSITARIO LA FE   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; ENTECAVIR; HEPATITIS B ANTIBODY; HEPATITIS B CORE ANTIBODY; HEPATITIS B CORE ANTIGEN; HEPATITIS B SURFACE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; LAMIVUDINE; VIRUS DNA;

ANTIBODY TITER; ANTIVIRAL RESISTANCE; DNA DETERMINATION; DONOR SELECTION; DRUG EFFICACY; EDITORIAL; GRAFT SURVIVAL; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HUMORAL IMMUNITY; INFECTION RISK; LIVER CIRRHOSIS; LIVER GRAFT; LIVER TRANSPLANTATION; MEDICAL DECISION MAKING; MORTALITY; PATIENT MONITORING; POLYMERASE CHAIN REACTION; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROPHYLAXIS; RISK ASSESSMENT; TREATMENT DURATION; TREATMENT INDICATION; TREATMENT OUTCOME; VIRUS IDENTIFICATION; VIRUS REACTIVATION; VIRUS TRANSMISSION;

EID: 70350563950     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.21814     Document Type: Editorial

References (36)

1. Chazouilleres O, Mamish D, Kim M, Carey K, Ferrell L, Roberts JP, et al. "Occult" hepatitis B virus as source of infection in liver transplant recipients. Lancet 1994;343:142-146.
2. Pruett TL. Editorial response: de novo HBV infections after liver transplantation. Liver Transpl Surg 1998;4:182-184.
3. Prieto M, Gómez MD, Berenguer M, Córdoba J, Rayón JM, Pastor M, et al. De novo hepatitis B after liver transplantation from hepatitis B core antibody-positive donors in an area with high prevalence of anti-HBc positivity in the donor population. Liver Transpl 2001;7:51-58. (Pubitemid 32060915)
4. Roque-Afonso AM, Feray C, Samuel D, Simoneau D, Roche B, Emile JF, et al. Antibodies to hepatitis B surface antigen prevent viral reactivation in recipients of liver grafts from anti-HBC positive donors. Gut 2002;50:95-99. (Pubitemid 34028310)
5. Nery JR, Nery-Avila C, Reddy KR, Cirocco R, Weppler D, Levi DM, et al. Use of liver grafts from donors positive for antihepatitis B-core antibody (anti-HBc) in the era of prophylaxis with hepatitis-B immunoglobulin and lamivudine. Transplantation 2003;75:1179-1186. (Pubitemid 36513018)
6. Samuel D, Forns X, Berenguer M, Trautwein C, Burroughs A, Rizzetto M, et al. Report of the monothematic EASL conference on liver transplantation for viral hepatitis (Paris, France, January 12-14, 2006). J Hepatol 2006;45:127-143. (Pubitemid 43850627)
7. Chen YS, Wang CC, de Villa VH, Wang SH, Cheng YF, Huang TL, et al. Prevention of de novo hepatitis B virus infection in living donor liver transplantation using hepatitis B core antibody positive donors. Clin Transplant 2002;16:405-409.
8. de Villa VH, Chen YS, Chen CL. Hepatitis B core antibodypositive grafts: recipient's risk. Transplantation 2003;75(suppl):S49-S53.
9. Gallegos-Orozco JF, Vargas HE, Rakela J. Virologically compromised donor grafts in liver transplantation. J Hepatol 2004;41:512-521. (Pubitemid 39297785)
10. Prieto M, Rubín A, Berenguer M, Aguilera V, Benlloch S, Ortiz C. Use of grafts from HBsAg-negative HBcAb-positive donors in Liver Transplantation: long-term results of a selective assignation strategy. Hepatology 2008;48(4 suppl):576A.
11. Su WJ, Ho MC, Ni YH, Chen HL, Hu RH, Wu YM, et al. High-titer antibody to hepatitis B surface antigen before liver transplantation can prevent de novo hepatitis B infection. J Pediatr Gastroenterol Nutr 2009;48:203-208.
12. Arslan M, Wiesner RH, Sievers C, Egan K, Zein NN. Double- dose accelerated hepatitis B vaccine in patients with end-stage liver disease. Liver Transpl 2001;7:314-320. (Pubitemid 32331535)
13. Dumortier J, Chevallier P, Scoazec JY, Boillot O. HBV reactivation in the recipient of a liver graft from an anti- HBc positive donor despite post-vaccination antibodies to hepatitis B surface antigen. J Hepatol 2002;37:876-877. (Pubitemid 35404234)
14. Dickson RC, Everhart JE, Lake JR, Wei Y, Seaberg EC, Wiesner RH, et al. Transmission of hepatitis B by transplantation of livers from donors positive for antibody to hepatitis B core antigen. The National Institute of Diabetes and Digestive and Kidney Diseases Liver Transplantation Database. Gastroenterology 1997;113:1668-1674. (Pubitemid 27461255)
15. Perrillo R. Hepatitis B virus prevention strategies for antibody to hepatitis B core antigen-positive liver donation: a survey of North American, European, and Asian-Pacific transplant programs. Liver Transpl 2009;15:223-232.
16. Prakoso E, Strasser SI, Koorey DJ, Verran D, McCaughan GW. Long-term lamivudine monotherapy prevents development of hepatitis B virus infection in hepatitis B surface- antigen negative liver transplant recipients from hepatitis B core-antibody-positive donors. Clin Transplant 2006;20:369-373. (Pubitemid 43880574)
17. Jain A, Orloff M, Abt P, Kashyap R, Mohanka R, Lansing K, et al. Use of hepatitis B core antibody-positive liver allograft in hepatitis C virus-positive and -negative recipients with use of short course of hepatitis B immunoglobulin and lamivudine. Transplant Proc 2005;37:3187-3189. (Pubitemid 41435658)
18. Yen RD, Bonatti H, Mendez J, Aranda-Michel J, Satyanarayana R, Dickson RC. Case report of lamivudineresistant hepatitis B virus infection post liver transplantation from a hepatitis B core antibody donor. Am J Transplant 2006;6(pt 1):1077-1083. (Pubitemid 44356661)
19. Dodson SF, Bonham CA, Geller DA, Cacciarelli TV, Rakela J, Fung JJ. Prevention of de novo hepatitis B infection in recipients of hepatic allografts from anti-HBc positive donors. Transplantation 1999;68:1058-1061. (Pubitemid 29489337)
20. Uemoto S, Sugiyama K, Marusawa H, Inomata Y, Asonuma K, Egawa H, et al. Transmission of hepatitis B virus from hepatitis B core antibody-positive donors in living related liver transplants. Transplantation 1998;65:494-499. (Pubitemid 28136490)
21. Umeda M, Marusawa H, Ueda M, Takada Y, Egawa H, Uemoto S, et al. Beneficial effects of short-term lamivudine treatment for de novo hepatitis B virus reactivation after liver transplantation. Am J Transplant 2006;6:2680-2685. (Pubitemid 44571688)
22. Roche B, Roque-Afonso AM, Antonini T, Gigou M, Castaing D, Samuel D. What is the risk of HBV transmission in recipients of liver graft from HBc-positive antibody HBs-negative antigen donors? A single center experience over 10 years. Hepatology 2007;46(4 suppl):479A.
23. Loss GE, Mason AL, Blazek J, Dick D, Lipscomb J, Guo L, et al. Transplantation of livers from HBc Ab positive donors into HBc Ab negative recipients: a strategy and preliminary results. Clin Transplant 2001;15(suppl 6):55-58. (Pubitemid 33062048)
24. Fábrega E, García-Suarez C, Guerra A, Orive A, Casafont F, Crespo J, et al. Liver transplantation with allografts from hepatitis B core antibody-positive donors: a new approach. Liver Transpl 2003;9:916-920. (Pubitemid 37098839)
25. Raimondo G, Allain JP, Brunetto MR, Buendia MA, Chen DS, Colombo M, et al. Statements from the Taormina expert meeting on occult hepatitis B virus infection. J Hepatol 2008;49:652-657.
26. Douglas DD, Rakela J, Wright TL, Krom RA, Wiesner RH. The clinical course of transplantation-associated de novo hepatitis B infection in the liver transplant recipient. Liver Transpl Surg 1997;3:105-111. (Pubitemid 27114021)
27. Loss GE Jr, Mason AL, Nair S, Blazek J, Farr G, Guo L, et al. Does lamivudine prophylaxis eradicate persistent HBV DNA from allografts derived from anti-HBc-positive donors? Liver Transpl 2003;9:1258-1264.
28. Chang SH, Suh KS, Yi NJ, Choi SH, Lee HJ, Seo JK, et al. Active immunization against de novo hepatitis B virus infection in pediatric patients after liver transplantation. Hepatology 2003;37:1329-1334.
29. Lin CC, Chen CL, Concejero A, Wang CC, Wang SH, Liu YW, et al. Active immunization to prevent de novo hepatitis B virus infection in pediatric live donor liver recipients. Am J Transplant 2007;7:195-200. (Pubitemid 44952873)
30. Park JB, Kwon CH, Lee KW, Choi GS, Kim DJ, Seo JM, et al. Hepatitis B virus vaccine switch program for prevention of de novo hepatitis B virus infection in pediatric patients. Transpl Int 2008;21:346-352.
31. Crespo J, Fábrega E, Casafont F, Rivero M, de las Heras G, de la Peña J, et al. Severe clinical course of de novo hepatitis B infection after liver transplantation. Liver Transpl Surg 1999;5:175-183.
32. Segovia R, Sánchez-Fueyo A, Rimola A, Grande L, Bruguera M, Costa J, et al. Evidence of serious graft damage induced by de novo hepatitis B virus infection after liver transplantation. Liver Transpl 2001;7:106-112. (Pubitemid 32166515)
33. Castells L, Vargas V, Rodríguez F, Allende H, Buti M, Sánchez-Avila JF, et al. Clinical impact and efficacy of lamivudine therapy in de novo hepatitis B infection after liver transplantation. Liver Transpl 2002;8:892-900. (Pubitemid 35154018)
34. Yu L, Koepsell T, Manhart L, Ioannou G. Survival after orthotopic liver transplantation: the impact of antibody against hepatitis B core antigen in the donor. Liver Transpl 2009;15:1343-1350.
35. Burton JR Jr, Shaw-Stiffel TA. Use of hepatitis B core antibody-positive donors in recipients without evidence of hepatitis B infection: a survey of current practice in the United States. Liver Transpl 2003;9:837-842.
36. Joya-Vazquez PP, Dodson FS, Dvorchik I, Gray E, Chesky A, Demetris AJ, et al. Impact of anti-hepatitis Bc-positive grafts on the outcome of liver transplantation for HBV-related cirrhosis. Transplantation 2002;73:1598-1602. (Pubitemid 34568672)